The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Michael E. Nassif(Saint Luke's Hospital), Mikhail Kosiborod(Copenhagen University Hospital), Sanjiv J. Shah(National Heart Lung and Blood Institute), Sheryl L. Windsor(Saint Luke's Hospital), Sumant Lamba(First Coast Cardiovascular Institute), Gregory D. Lewis(Massachusetts General Hospital), Susan Joseph(University of Maryland, Baltimore), Barry A. Borlaug(Mayo Clinic in Arizona), Barry S. Clemson(OSF HealthCare), Michael Pursley(The Heart House), Manreet Kanwar(Allegheny Health Network), Kavita Sharma(Johns Hopkins University), Taiyeb Khumri(Saint Luke's Hospital), Ali O. Malik(Saint Luke's Hospital), Dalane W. Kitzman(Wake Forest University), Guillermo E. Umpierrez(Emory University), Lokesh Chandra, Sunit‐Preet Chaudhry(St. Vincent Hospital), Yevgeniy Khariton(Saint Luke's Hospital), John Ryan(Virginia Commonwealth University), Sadiya S. Khan(Northwestern University), Fengming Tang(Saint Luke's Hospital), C. Chow(Stormont Vail Health), Michael Fong(University of Southern California), Elias S. Siraj(Eastern Virginia Medical School), Robert Gordon(NorthShore University HealthSystem)
Cited by 599
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k